Meanwhile, two phase I clinical trials have evaluated the safety and potential of systemic treatment with sodium stibogluconate (SSG), a licensed leishmaniasis treatment that also acts as an active-site inhibitor of both PTPN6 and the related SHP-2 (40, 41). Here, PTPN6 is linked to leishmaniasis.